alpha-Adrenergic Agonist Drug Class List

Drugs in Drug Class: alpha-Adrenergic Agonist

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Endo Operations	ADRENALIN	epinephrine	SOLUTION;INTRAVENOUS	215875-001	Apr 21, 2023		RX	Yes	Yes			Y
Endo Operations	ADRENALIN	epinephrine	SOLUTION;INTRAVENOUS	215875-005	Apr 21, 2023		RX	Yes	Yes			Y
Endo Operations	ADRENALIN	epinephrine	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS	204640-001	Dec 18, 2013	AP	RX	Yes	Yes			Y
Endo Operations	ADRENALIN	epinephrine	SOLUTION;INTRAVENOUS	215875-003	Apr 21, 2023		RX	Yes	Yes			Y
Endo Operations	ADRENALIN	epinephrine	SOLUTION;INTRAVENOUS	215875-001	Apr 21, 2023		RX	Yes	Yes			Y

Alpha-Adrenergic Agonist Market Analysis and Financial Projection

The alpha-adrenergic agonist market is a dynamic segment of the pharmaceutical industry, driven by therapeutic demand for conditions like hypertension, ADHD, and glaucoma. Below is an analysis of its market dynamics and patent landscape:

---

Market Dynamics

Drivers

1. Disease Prevalence: Rising global cases of hypertension, ADHD, and glaucoma are key growth catalysts. Chronic diseases account for 47% of U.S. adult hypertension cases, fueling demand for alpha1 agonists [4][6].
2. Drug Innovation: Extended-release formulations and combination therapies (e.g., solubility-enhanced compositions) improve efficacy and compliance. For example, stabilized formulations using carboxymethylcellulose enhance drug delivery [2][10].
3. Emerging Markets: Asia-Pacific and Latin America show high growth potential due to healthcare infrastructure improvements and urbanization [1][7].

Restraints

• Side Effects: Adverse reactions like hypotension and dry mouth limit adoption, particularly for alpha2 agonists used in mental health [6][8].
• Regulatory Hurdles: Stringent FDA/EMA approval processes delay drug launches, especially in developing nations [1][6].
• Cost Barriers: Branded therapies remain expensive, restricting access in low-income regions [1].

Opportunities

• Personalized Medicine: Genetic profiling enables targeted therapies, with R&D exploring applications in pain management and opioid withdrawal [1][6].
• New Indications: Alpha2 agonists are increasingly used in opioid addiction treatment, aligning with global harm-reduction strategies [6].

---

Growth Projections

Segment	2024 Market Size	2033 Projection	CAGR
Alpha1 Agonists	$2.5B [4]	$4.8B [4]	7.8%
Alpha2 Agonists	$1.45B [6]	$2.35B [6]	5.5%
Regional Share	North America (40%), Europe (30%), Asia-Pacific (20%) [7]

---

Key Players

• Alpha1 Agonists: Merck, Boehringer Ingelheim, Teva (leveraging cost-effective generics) [3][7].
• Alpha2 Agonists: Novartis, Allergan (focusing on CNS therapeutics) [3][6].
• Revenue: Top companies report billions in annual sales, with alpha-adrenergic agonist markets collectively valued at hundreds of millions [3][6].

---

Patent Landscape

Core Innovations

1. Formulation Stability:
   • Patent US-7569230-B2 (Novalar Pharmaceuticals): Stabilized alpha2 agonists for reversing anesthetic effects [2].
   • US8858961B2 (Allergan): Solubility-enhanced compositions using carboxymethylcellulose [10].
2. Therapeutic Expansion:
   • US20140121257A1: Alpha1 agonists for improving cardiac and brain function [9].
   • Patent 6,673,337 (Allergan): Compositions combining alpha2 agonists with solubility enhancers [5].

Strategic Trends

• Assignee Focus: Allergan dominates with multiple patents for formulation improvements [5][8][10].
• Expiring Patents: Post-2030 expirations (e.g., US8858961B2) may increase generic competition [8].

---

Future Outlook

The market will see sustained growth through 2033, driven by:

• R&D Investment: Focus on minimizing side effects and expanding into neuropsychiatry.
• Regional Expansion: Asia-Pacific’s healthcare accessibility initiatives, particularly in China and India [1][7].
• Sustainability: Eco-friendly production methods and green chemistry adoption in manufacturing [1].

Highlight: "The rise of personalized medicine and transdermal delivery systems will redefine therapeutic precision in this sector." [1][6]

References

1. https://sites.google.com/view/paramountedgeconsulting/home/top-trending-reports/%C3%AE-adrenergic-agonist-market-analysis-current-landscape-and-future-outlook
2. https://pubchem.ncbi.nlm.nih.gov/patent/US-7569230-B2
3. https://github.com/jugutstam/Market-Research-Report-List-1/blob/main/a2-adrenergic-agonist-market.md
4. https://www.verifiedmarketreports.com/product/alpha1-adrenergic-agonist-market/
5. https://www.drugpatentwatch.com/p/patent/6673337
6. https://www.verifiedmarketreports.com/product/alpha-2-adrenergic-agonist-market/
7. https://github.com/pilukypalis/Market-Research-Report-List-1/blob/main/a1-adrenergic-agonist-market.md
8. https://www.drugpatentwatch.com/p/patent/8858961
9. https://patents.google.com/patent/US20140121257A1/en
10. https://patents.google.com/patent/US8858961B2/en
11. https://patents.google.com/patent/IL315798A/ko